NOT-NS-21-007: Notice of Intent to Publish a Funding Opportunity Announcement for Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed)

Notice of Intent to Publish a Funding Opportunity Announcement for Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed)

Notice Number:

NOT-NS-21-007

Key Dates

Release Date:

November 09, 2020

Estimated Publication Date of Funding Opportunity Announcement:

February 18, 2021

First Estimated Application Due Date:

June 17, 2021

Earliest Estimated Award Date:

March 01, 2022

Earliest Estimated Start Date:

March 15, 2022

Related Announcements

NOT-NS-21-006 - Notice of Intent to Publish a Funding Opportunity Announcement for Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)

NOT-NS-21-008 - Notice of Intent to Publish a Funding Opportunity Announcement for Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed)

Reissuance of PAR-18-762: Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed)

Issued by

National Institute of Neurological Disorders and Stroke (NINDS)

National Center for Complementary and Integrative Health (NCCIH)

Purpose

The purpose of this Notice is to inform potential applicants that the National Institute of Neurological Disorders and Stroke (NINDS) intends to publish a re-issuance of funding opportunity announcement (FOA) PAR-18-762.

This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.

The FOA is expected to be published in February 2021 with an expected application due date in the summer of 2021.

This FOA will utilize the R61/R33 (Clinical Trial Not Allowed) activity code. Details of the planned FOA are provided below.

Research Initiative Details

This funding opportunity announcement (FOA) encourages research grant applications to develop in vitro and/or ex vivo assays and conduct iterative screening efforts to identify and characterize potential therapeutic agents for neurological disorders. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the Blueprint Neurotherapeutics Network (BPN) or other translational programs.

Applicants are strongly encouraged to consult with NIH program staff as plans for an application are being developed.

Funding Information

Estimated Total Funding

TBD

Expected Number of Awards

TBD

Estimated Award Ceiling

Direct costs cannot exceed $499,000 in any one year. Cumulative direct costs for the entire 3-year project period may not exceed $750,000.

Primary CFDA Numbers

93.853

Anticipated Eligible Organizations

Public/State Controlled Institution of Higher Education
Private Institution of Higher Education
Nonprofit with 501(c)(3) IRS Status (Other than Institution of Higher Education)
Small Business
For-Profit Organization (Other than Small Business)
State Government
County governments
Indian/Native American Tribal Government (Federally Recognized)
Indian/Native American Tribal Government (Other than Federally Recognized)
Eligible Agencies of the Federal Government
U.S. Territory or Possession
Independent school districts
Public housing authorities/Indian housing authorities
Indian/Native American Tribally Designated Organization (Native American tribal organizations (other than Federally recognized tribal governments)
Regional Organization
Non-domestic (non-U.S.) Entity (Foreign Organization)

Applications are not being solicited at this time.

Inquiries

Please direct all inquiries to:

Rebecca Roof, PhD
National Institute of Neurological Disorders and Stroke (NINDS)
301-496-1779
rebecca.roof@nih.gov

Julia Bachman, PhD
National Institute of Neurological Disorders and Stroke (NINDS)
301-496-1779
julia.bachman@nih.gov

Craig Hopp, PhD
National Center for Complementary and Integrative Health (NCCIH)
301-496-5825
hoppdc@nih.gov